RegulatoryCompany release

Wave plans two-year WVE-006 registrational trial in AATD after FDA alignment on accelerated path

🇺🇸 Wave Life Sciences, Inc. (WVE) · Tue 27 Oct 2026

Wave Life Sciences says the FDA has aligned with a one-year interim analysis on AATD biomarkers that could support accelerated approval of its RNA editing therapy WVE-006.

Wave Life Sciences has said it is planning a two-year registrational trial of WVE-006, its RNA editing therapy for alpha-1 antitrypsin deficiency (AATD) in patients with the Pi*ZZ genotype. The company set out the plan in its third-quarter 2026 update, dated 27 October 2026.

A one-year interim analysis from the study would support a potential application for accelerated approval, based on AATD biomarkers. Wave said this follows alignment with the US Food and Drug Administration reached in October 2026.

The company added that the FDA also supports its liquid chromatography-mass spectrometry (LC-MS) assay for measuring M-AAT and Z-AAT protein. The summary available does not give further detail on trial size, endpoints or timelines for the start of enrolment.

Wave also outlined other pipeline steps. It plans to file a clinical trial application (CTA) for WVE-008, a candidate for PNPLA3-related liver disease, in the fourth quarter of 2026. It also expects to start a maintenance trial of WVE-007 in obesity in the same quarter.

As general context, accelerated approval in the US allows a medicine for a serious condition to be approved on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, usually with confirmatory evidence required afterwards.

What it means for your team

  • Regulatory teams should note the reported FDA alignment on a biomarker-based interim analysis as a route to potential accelerated approval in AATD, although the full agreement terms are not available.
  • Support for Wave's LC-MS assay for M-AAT and Z-AAT suggests bioanalytical method choice and validation will be central to the data package.
  • Developers in AATD and other genetic liver diseases may watch how biomarker endpoints are accepted, which could affect trial design and later market-access evidence needs.

Company's press release (SEC filing): Wave Life Sciences, Inc. ↗

Article written by VigiEye from the official source (Wave Life Sciences, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →